Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 5/20 | 0.39 |
| ▸ | PPARD | Q03181 | 3/20 | 0.31 |
| ▸ | PPARA | Q07869 | 3/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | LIG1 | P18858 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2653466 | 1.00 | DAO (0.39) | DAOPPARDPPARAPKMLIG1 | |
| SCHEMBL13647239 | 0.90 | DAO (0.40) | DAOPPARDPPARAPKMLIG1 | |
| SCHEMBL3333287 | 0.87 | HDAC3 (0.44) | PPARDPPARAHPGD | |
| SCHEMBL2654040 | 0.87 | HDAC3 (0.44) | PPARDPPARAHPGD | |
| SCHEMBL2655094 | 0.85 | KMT2A (0.39) | — | |
| SCHEMBL2655092 | 0.85 | KMT2A (0.39) | — | |
| SCHEMBL2654121 | 0.84 | HDAC4 (0.31) | — | |
| SCHEMBL3329420 | 0.84 | HDAC3 (0.34) | PPARDPPARA | |
| SCHEMBL2653853 | 0.84 | DAO (0.38) | DAOPKMLIG1HPGD | |
| SCHEMBL2653852 | 0.84 | DAO (0.38) | DAOPKMLIG1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084489-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100137417-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2010-06-03 | — | — | US | disclosed |
| EP-1856090-B1 | SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2009-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137417-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | DAO 2256/4885PPARD 145/4885PPARA 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.